Dr. Aithal on the HERceptin Adjuvant (HERA) Trial
October 25th 2012
Sramila Aithal, MD, from Cancer Treatment Centers of America, discusses the HERceptin Adjuvant (HERA) trial that examined adjuvant therapy with trastuzumab for women with HER2-positive early breast cancer.